**Abstract**

SV2A is a prototype synaptic vesicles protein and regulates action potential-dependent synaptic release of neurotransmitter. We previously reported that SV2A mutant rats, carrying a missense mutation (L174Q) in the *Sv2a* gene, showed impaired hippocampal GABA release and enhanced seizure susceptibility. Since recent studies reported a significant association of genetic SV2A polymorphism with schizophrenia (Schizophr. Res., 141, 262, 2012), we performed *in vivo* microdialysis and behavioral studies using the SV2A mutant rats to evaluate the role of SV2A in controlling accumbal dopaminergic neurotransmission. *In vivo* microdialysis studies showed that the *Sv2a* gene mutation significantly increased both depolarization (100 mM K^+^)- and methamphetamine (MAP, 100 µM)-induced dopamine release in the nucleus accumbens (NAc) without affecting basal dopamine release and dopamine contents. In behavioral studies, MAP (1 mg/kg, i.p.)-induced hyperlocomotion was significantly augmented by the *Sv2a* gene mutation. Haloperidol (0.5 mg/kg, i.p.) completely suppressed MAP-induced hyperlocomotion both in SV2A mutant and control (F344) rats. In addition, development of locomotor sensitization (reverse tolerance) to repeated MAP treatments (0.3 mg/kg/day, 12 days) was significant enhanced in SV2A mutant rats as compared to F344 rats. The present results suggest that dysfunction of SV2A by the missense mutation (L174Q) enhances synaptic dopamine release in the NAc, which may be linked to vulnerability to psychotic disorders.
